孟鲁司特钠联合复方甲氧那明治疗慢性支气管炎的临床疗效及对肺功能的影响

Clinical Effect of Montelukast Sodium Combined with Compound Methoxyphenamine in the Treatment of Chronic Bronchitis and its Influence on Pulmonary Function

目的研究孟鲁司特钠联合复方甲氧那明治疗慢性支气管炎的临床疗效及对肺功能的影响。方法选取2020年4月-2021年4月于我院诊治的72例慢性支气管炎患者为研究对象,采用随机数字表法分为对照组和观察组,各36例。对照组采用孟鲁司特钠治疗,观察组在对照组基础上联合复方甲氧那明治疗,比较两组临床疗效、肺功能指标、炎症因子指标、临床症状缓解时间、不良反应发生率。结果观察组治疗总有效率为94.44%,高于对照组的80.56%(P<0.05);两组治疗后呼气峰流速(PEF)、肺活量(FVC)、第1秒用力呼气量(FEV1)均高于治疗前,且观察组高于对照组(P<0.05);两组治疗后C反应蛋白(CRP)、白细胞(WBC)水平均低于治疗前,且观察组低于对照组(P<0.05);观察组咳嗽、喘息、咳痰各症状缓解时间均短于对照组(P<0.05);观察组不良反应发生率为5.56%,低于对照组的8.33%,但差异无统计学意义(P>0.05)。结论孟鲁司特钠联合复方甲氧那明治疗慢性支气管炎疗效确切,可提高总有效率,改善肺功能指标,促进炎症因子吸收,快速缓解临床症状,且不会增加不良反应。

Objective To study the clinical efficacy of montelukast sodium combined with compound methoxyphenamine in the treatment of chronic bronchitis and its effect on pulmonary function.Methods A total of 72 patients with chronic bronchitis diagnosed and treated in our hospital from April 2020 to April 2021 were selected as the research objects.They were divided into control group and observation group by random number table method,with 36 cases in each group.The control group was treated with montelukast sodium,and the observation group was treated with compound methoxyphenamine on the basis of the control group.The clinical efficacy,pulmonary function index,inflammatory factor index,clinical symptom relief time and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 94.44%,which was higher than 80.56%of the control group(P<0.05).The peak expiratory flow(PEF),forced vital capacity(FVC)and the forced expiratory volume in one second(FEV1)of the two groups after treatment were higher than those before treatment,and those in the observation group wwere higher than those in the control group(P<0.05).After treatment,the levels of C-reactive protein(CRP)and white blood cell(WBC)in the two groups were lower than those before treatment,and those in the observation group were lower than those in the control group(P<0.05).The remission time of cough,wheezing and expectoration in the observation group was shorter than that in the control group(P<0.05).The incidence of adverse reactions in the observation group was 5.56%,which was lower than 8.33%in the control group,but there is no significant difference(P>0.05).Conclusion Montelukast sodium combined with compound methoxyphenamine is effective in the treatment of chronic bronchitis,which can improve the total effective rate,improve lung function index,promote the absorption of inflammatory factors,quickly relieve clinical symptoms,and will not increase adverse reactions.